<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00156026</url>
  </required_header>
  <id_info>
    <org_study_id>OCOG-2000-CIN1</org_study_id>
    <nct_id>NCT00156026</nct_id>
  </id_info>
  <brief_title>Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1</brief_title>
  <official_title>Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study looks at immediate treatment of a cervix with CIN 1 versus regular six-month&#xD;
      follow-up with colposcopy and treatment if CIN 1 progresses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In women who present with biopsy-proven CIN 1, to compare the management approach of regular&#xD;
      colposcopic follow-up and only treating progressive disease using the LEEP, with an approach&#xD;
      of immediate treatment using LEEP. The primary outcome is progression to more advanced&#xD;
      disease (i.e., CIN 2, CIN 3 or cancer).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression to more advanced disease</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>persistent CIN 1 after 18 months</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predict disease persistence or progression</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">415</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate Treatment - LEEP - Loop electrosurgical excision procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Colposcopic Follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>loop electrosurgical excision procedure (LEEP)</intervention_name>
    <description>1. loop electrosurgical excision procedure</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible patients will:&#xD;
&#xD;
               -  have documented CIN 1 by histologic assessment as the highest grade lesion&#xD;
                  present,&#xD;
&#xD;
               -  have the lesion confined to the cervix and completely visualized,&#xD;
&#xD;
               -  be 16 years or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any one of the following will be an excluding characteristic:&#xD;
&#xD;
               -  index Pap smear showing CIN 2, CIN 3 or cancer;&#xD;
&#xD;
               -  index Pap smear shows atypical glandular cells of unknown significance, glandular&#xD;
                  dysplasia, or malignancy requiring immediate investigation;&#xD;
&#xD;
               -  patients with previously identified CIN 1 by biopsy who are already in a&#xD;
                  colposcopic surveillance program;&#xD;
&#xD;
               -  unsatisfactory colposcopic exam defined as inability to see the extent of the&#xD;
                  lesion in the endocervical canal or absence of a lesion on the ectocervix but&#xD;
                  endocervical curettage shows CIN 1;&#xD;
&#xD;
               -  pregnancy;&#xD;
&#xD;
               -  prior therapy for dysplasia including medical (5FU), surgical (Laser, LEEP) or&#xD;
                  cryotherapy;&#xD;
&#xD;
               -  prior gynecologic cancer;&#xD;
&#xD;
               -  prior pelvic radiation therapy;&#xD;
&#xD;
               -  inability to attend outpatient follow-up visits because of geographic&#xD;
                  inaccessibility;&#xD;
&#xD;
               -  other malignancies except non-melanoma skin cancer;&#xD;
&#xD;
               -  immunosuppression due to diseases such as AIDS, organ transplantation, or on&#xD;
                  immunosuppressive medications such as prednisone, imuran or chemotherapy for&#xD;
                  diseases like systemic lupus;&#xD;
&#xD;
               -  cognitively impaired or otherwise unable to obtain written informed consent;&#xD;
&#xD;
               -  extension of the CIN 1 lesion to vagina or a separate vaginal lesion showing&#xD;
                  dysplasia;&#xD;
&#xD;
               -  colposcopically visible condyloma outside of the transformation zone;&#xD;
&#xD;
               -  known allergy to local analgesics;&#xD;
&#xD;
               -  clinically evident vaginitis must be treated and resolved prior to entry on the&#xD;
                  trial;&#xD;
&#xD;
               -  inability to read and respond in English/French;&#xD;
&#xD;
               -  failure to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurie Elit, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Juravinski Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Levine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ontario Clinical Oncology Group (OCOG)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jim Julian, MMath</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University, Dept of Clinical Epidemiology &amp; Biostatistics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidade Estadual de Campinas</name>
      <address>
        <city>Campinas</city>
        <zip>CEP 13083-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Fernandes Figueira - Oswaldo Cruz Foundation</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>CEP 22250-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B.C. Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Cancer Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brantford General Hospital</name>
      <address>
        <city>Brantford</city>
        <state>Ontario</state>
        <zip>N3T 3J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences - Henderson Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8P 3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 3H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital du Saint-Sacrement</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 2L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>January 28, 2009</last_update_submitted>
  <last_update_submitted_qc>January 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Mark Levine</name_title>
    <organization>Ontario Clinical Oncology Group</organization>
  </responsible_party>
  <keyword>CIN 1</keyword>
  <keyword>cervical intraepithelial neoplasia</keyword>
  <keyword>cervix</keyword>
  <keyword>cancer</keyword>
  <keyword>loop electrosurgical excision procedure</keyword>
  <keyword>LEEP</keyword>
  <keyword>expectant management</keyword>
  <keyword>human papilloma virus</keyword>
  <keyword>HPV</keyword>
  <keyword>colposcopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

